Home › Companies › RCKT

Rocket Pharmaceuticals

Market cap $236M 111.7M shares (10-Q, Nov 6, 2026) × $2.11 close Nov 17, 2026

Most recent annual filing: 2026-02-15

Catalyst timeline

1 trackedQuarter catalyst calendar →
  1. RP-A601 PKP2-ACM readout2H 2026RP-A601 PKP2-ACM readout, 2H 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Discontinued (2)

Capital (as filed)

Cash
$95.5M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$174M Sep 30, 2026
Long-term investments
$9.9M Sep 30, 2026
Operating cash flow
−$39.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$279M cash, runway Q3 2028 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (9 calls)

Every verdict Biotech Distilled has published on Rocket Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Rocket Pharmaceuticals (RCKT): Scientific Deep Dive for Lead and Pipeline Products Compelling mid-to-late-stage gene therapy assets but severe AAV toxicity risk and imminent dilution warrant waiting for the PDUFA decision and post-dilution entry.
  2. Hold UPDATE: Rocket Pharmaceuticals (RCKT) - Rocket Deploys KRESLADI Patch, But Internal Code Shows Severe Tech Debt KRESLADI accelerated approval is a genuine win but the commercial market is tiny, dilution overhang is suffocating, and the AAV Danon trial safety question remains the key gating event.
  3. Hold speculative UPDATE: Rocket Pharmaceuticals (RCKT) - The PRV Lands at $180M, Runway Bought Through Q2 2028 The $180M PRV sale materially narrows the dilution gap and extends runway to Q2 2028, improving asymmetry enough to warrant a small starter position ahead of the Danon Phase 2 safety readout.
  4. Speculative buy speculative UPDATE: Rocket Pharmaceuticals (RCKT) - The Danon Clock is Running Danon Phase 2 dosing reinitiated on schedule and Q1 burn confirms post-restructuring cost structure is real, but the capillary leak binary remains unresolved so conviction and sizing are unchanged.
  5. Buy core UPDATE: Rocket Pharmaceuticals (RCKT) - The Canary Came Back Out of the Mine All three Danon Phase 2 patients cleared safety with zero capillary leak or TMA at the recalibrated dose, materially retiring the platform-failure tail risk and improving asymmetry enough to upgrade from speculative to core buy.
  6. Buy core UPDATE: Rocket Pharmaceuticals (RCKT) - The Observation Window Closed Clean All three Danon patients completed the full protocol-defined safety observation window with no TMA or capillary leak, confirming and extending the August 3 upgrade with $283.7M cash and an untapped ATM.
  7. Buy core UPDATE: Rocket Pharmaceuticals (RCKT) - The FDA Answered, and the Answer Has a Date Attached FDA confirmed the 12-patient pivotal population, recalibrated dose, and co-primary endpoints, retiring regulatory uncertainty, but dosing through mid-2027 pushes the efficacy read to mid-2028 near the runway limit.
  8. Speculative buy speculative UPDATE: Rocket Pharmaceuticals (RCKT) - The Webinar Showed Everything Except the Answer No efficacy data from the recalibrated dose was shown, a Hercules IP lien now sits ahead of equity, a Phase 1 transplant raises durability questions, and the runway barely reaches the 2028 readout, warranting a downgrade to lottery-ticket sizing.
  9. Speculative buy speculative UPDATE: Rocket Pharmaceuticals (RCKT) - Two Overhangs Cleared, One Binary Left Core securities claims dismissed and BAG3 dosed its first patient, but no efficacy data at the recalibrated dose exists and the stock remains a binary bet on a mid-2028 Danon readout priced near cash.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (32)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

11 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)